Pharmacotherapy Specialty Review Course for Recertification, Core Therapeutic Modules + RECERT EXAMS Package (Cert # L199336)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 10/23/2019
Content Release Date: 11/20/2019
Expiration Date: 11/17/2020
Activity Type: Application-based
CE Credits: 21 (BPS and ACPE)
Activity Fee: $475 (ASHP member); $675 (non-member) 

Accreditation for Pharmacists

The American Society of Health-System Pharmacistsis accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 

Target Audience

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in pharmacotherapy pharmacy.

Activity Overview

This course is intended for BCPS in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS) to provide an overview of recent standards and guidelines that specialists should be familiar with in practice. The course uses a case-based approach to discuss patient care issues. In this series, faculty will:

  • Review pertinent clinical topics and practice skills
  • List valuable resources for further self-study 

 This online course consists of 16 activities (see tables below) and provides up to 21 hours of continuing pharmacy education credit.

Recertification Credit*

Board certified pharmacists are eligible to receive up to 21 hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed.  You are allowed only one attempt to successfully complete this assessment.

This course is not intended for those preparing to take the BPS Pharmacotherapy Specialty Examination for Certification. To prepare for the examination, please see courses here: http://elearning.ashp.org/catalog/ptherapy-review

These activities are part of the ASHP professional development program for BCPS recertification approved by the BPS.

* Please note: Review Course for Recertification may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle.

Review Course

PLEASE NOTE: REVIEW COURSE MATERIAL WILL BE AVAILABLE 2/5/2020.

The review course will be available February 5, 2020. These activities will be recorded during a live educational event on December 7-8, 2019 in Las Vegas, Nevada. Learners who claimed credit for the live activities, should not claim credit for the home study activities. 

Learning Activity

ACPENumber

Credit

Hours

*Assessment Pass Point

Pharmacotherapy Review and Recertification Course: Cardiovascular Disease: Primary Prevention Case

0204-0000-19-610-H01-P

1.5

69%

Pharmacotherapy Review and Recertification Course: Cardiovascular Disease: Secondary Prevention Case #1

0204-0000-19-608-H01-P

1.5

Pharmacotherapy Review and Recertification Course: Cardiovascular Disease: Secondary Prevention Case #2

0204-0000-19-612-H01-P

1.5

Pharmacotherapy Review and Recertification Course: Regulatory and Quality Issues

0204-0000-19-607-H03-P

1

 

Group 1 Assessment

5.5

 

Research Design, Methodology, Statistical Analysis, and Application

0204-0000-19-604-H04-P

2

72%

Pharmacotherapy Specialty Review and Recertification Course: Oncology and Supportive Care Case

0204-0000-19-611-H01-P

1.5

Pharmacotherapy Review and Recertification Course: Complex Nursing Home Patient Case

0204-0000-19-613-H01-P

1.5

 

Group 2 Assessment

5.0

 

Pharmacotherapy Specialty Review and Recertification Course: Medication Safety

0204-0000-19-606-H05-P

1

68%

Pharmacotherapy Specialty Review and Recertification Course: Complex HIV Case

0204-0000-19-605-H02-P

1.5

Pharmacotherapy Review and Recertification Course: Complex Pediatric Asthma Case

0204-0000-19-609-H01-P

1.5

Pharmacotherapy Specialty Review and Recertification Course: Complex Pneumonia Case

0204-0000-19-614-H01-P

1.5

 

Group 3 Assessment

5.5

 

Review Course Learning Objectives

After participating in this CPE activity, learners should be able to:

ACPE Number: 0204-0000-19-604-H04-P
  • Analyze biomedical literature with regard to study methodology, statistical analysis, and significance.
  • Explain the use of evidence-based treatment guidelines and protocols.
  •  Interpret the biomedical literature and its application to clinical practice.
  •  Identify appropriate sources of information to use in addressing questions that arise in one’s practice or from patients and other healthcare professionals.
  •  Explain how to provide education regarding the principles and practices of evidence-based medicine to current and future health care professionals.
ACPE Number: 0204-0000-19-605-H02-P
  • Select the appropriate treatment and monitoring for a complex patient-case with multiple conditions, including dyslipidemia, and hepatitis B.
  • Identify and manage common drug interactions experienced by HIV-treated patients.
  • Identify and manage common adverse drug reactions experienced by HIV-treated patients.
  •  Determine appropriate medication choices for the treatment and prevention of common opportunistic infections.
  • Discuss quality of life issues in terms of medication therapy for HIV-infected patients.
  • Identify and recommend appropriate resource organizations/groups to assist a specific patient.
ACPE Number: 0204-0000-19-606-H05-P

At the conclusion of the session the participant should be able to discuss national regulations and local (but universally adopted) practices related to:

  • Adverse drug reaction reporting.
  • Medication safety.
  • Formulary management.
  • Drug development and approval processes.
  • Ethical issues, such as appropriate interactions with industry, conflict of interest disclosures.
ACPE Number: 0204-0000-19-607-H03-P

At the conclusion of the session the participant should be able to discuss national regulations and local (but universally adopted) practices related to:

  • Quality metrics.
  • Agencies that oversee quality (governmental and non-governmental).
  • Major public health initiatives (e.g., REMS programs, Healthy People 2020, Core Measures).
  • Prescribing and monitoring specific drugs (e.g., methadone, isotretinoin, REMS programs).
  • Federal regulations related to patient’s rights and protections (e.g., privacy, child/adult protective services, advance directives, living will, power of attorney, do not resuscitate)"
ACPE Number: 0204-0000-19-608-H01-P
  • Select the appropriate treatment and monitoring for a complex patient-case with multiple conditions, including atrial fibrillation (AF), acute coronary syndromes (ACS), and gastroesophageal reflux disease (GERD).
  • Develop a plan to address continuity of care issues.
  • Formulate a medication therapy plan for smoking cessation.
  • Determine how to manage drug – drug and drug-induced disease interactions in a patient with ischemic heart disease.
  • Discuss quality of life in this population.
  • Discuss national benchmarking standards and implications to patient care.
ACPE Number: 0204-0000-19-609-H01-P
  • Select the optimal treatment and monitoring for a complex patient-case with acute asthma exacerbation, acute otitis media and seasonal allergies.
  • Determine methods for counseling a patient and/or caregiver regarding asthma self-management plan.
  • Formulate a plan for childhood vaccinations in a child who has been delayed in receiving them.
  • Discuss complimentary/alternative medicine and cultural issues in this population.
ACPE Number: 0204-0000-19-610-H01-P
  • Select the appropriate treatment and monitoring for a complex patient-case with multiple conditions, including hypertension, dyslipidemia, chronic kidney disease, diabetes, and obesity.
  • State the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices recommendations for adult immunizations.
  • Determine how to advise a patient on point-of-care testing to measure response to drug therapy.
  • Discuss national benchmarking standards and implications to patient care.
ACPE Number: 0204-0000-19-611-H01-P
  • Select the appropriate treatment and monitoring for a complex patient-case with multiple conditions, including breast cancer, febrile neutropenia and pulmonary embolism.
  • Compare and contrast current breast cancer screening recommendations.
  • Develop a plan to manage pain and nausea/vomiting in a patient with cancer.
  • Discuss safety issues in this population.
  • Discuss adherence issues with oral chemotherapy regimens.
ACPE Number: 0204-0000-19-612-H01-P
  • Select the appropriate treatment and monitoring for a complex patient-case with multiple conditions, including heart failure, electrolyte disturbances in acute decompensated heart failure, diabetes, and a thyroid disorder.
  • Discuss safety issues and health literacy in this population.
  • Discuss national benchmarking standards and implications to patient care.
ACPE Number: 0204-0000-19-613-H01-P
  • Select the appropriate treatment for a complex patient-case with multiple conditions, including stroke, depression/anxiety, dementia, chronic COPD management, osteoarthritis, osteoporosis, and pain.
  • Discuss complimentary/alternative medicine and safety issues in this population.
  • Discuss quality improvement initiatives and regulations in the nursing home setting.
ACPE Number: 0204-0000-19-614-H01-P
  • Select the appropriate treatment and monitoring for a complex patient-case with multiple conditions, including pneumonia, acute renal insufficiency, sepsis, COPD and dehydration.
  • Interpret clinical data, including lab, physical examination and vital signs.
  • Determine and prioritize pneumonia-related treatment goals.
  • Determine approaches to manage drug allergies and select next best drug therapy when primary drugs are precluded.
  • Discuss approaches to limiting antimicrobial over use by stewarding antibiotic usage appropriately.
  •  Discuss safety issues in patients receiving treatment for pneumonia.

Core Therapeutic Modules

The Core Therapeutic Modules for Recertification Package consists of 5 activities (see table below). In each activity, faculty review clinical topics and practice skills using a case-based approach. This package is intended for board certified pharmacists in need of recertification credit; the activities were designed based on the content outline developed by the Board of Pharmacy Specialties (BPS).

ACPE Number

Learning Module

Credit Hours

*Assessment Pass Point

0204-0000-19-615-H01-P

Select Topics in Infectious Diseases: Part 1

1.00

75%

0204-0000-19-616-H01-P

Select Topics in Infectious Diseases: Part 2

1.00

0204-0000-19-602-H01-P

Fluid, Electrolytes, and Nutrition

1.00

0204-0000-19-617-H01-P

Select Topics in Neurologic Disorders

1.00

0204-0000-19-618-H01-P

Diabetes

1.00

 

 

5

 

Core Therapeutic Learning Objectives

ACPE Number: 0204-0000-19-615-H01-P

For the following diseases: C. Difficile infection, skin and soft tissue infections, upper respiratory tract infections, community acquired pneumonia

  • Interpret laboratory and diagnostic tests.
  • Formulate the most appropriate treatment and monitoring plans based on patient-specific information and current guidelines.
  • Manage drug-related problems, evaluate response to therapy, and modify patient-specific treatment plans based on follow-up assessment.

ACPE Number: 0204-0000-19-616-H01-P

For the following diseases: sexually transmitted diseases, urinary tract infections, endocarditis, meningitis

  • Interpret laboratory and diagnostic tests.
  • Formulate the most appropriate treatment and monitoring plans based on patient-specific information and current guidelines.
  • Manage drug-related problems, evaluate response to therapy, and modify patient-specific treatment plans based on follow-up assessment.

ACPE Number: 0204-0000-19-602-H01-P

Interpret laboratory and diagnostic tests to evaluate fluid, electrolyte and nutrition status.

  • Select the appropriate route for nutrition administration, and evaluate if nutrition needs are being met based on patient-specific information and current guidelines.
  • Manage drug-related electrolyte interactions and nutrient interactions.
  • Determine the most appropriate therapy and monitoring in patients with fluid, electrolyte, and nutritional disorders based on patient-specific information and current guidelines.

ACPE Number: 0204-0000-19-617-H01-P

For patients with seizure disorders, Parkinson's Disease, migraine and sleep disorders:

  • Evaluate the risks and benefits of drug therapy considering other medication and patient specific factors.
  • Formulate the most appropriate treatment, monitoring and follow-up plans based on patient-specific information and current guidelines.
  • Manage drug-related problems and evaluate response to therapy.

ACPE Number: 0204-0000-19-618-H01-P

  • Interpret diagnostic and/or laboratory tests in patients with diabetes.
  • Formulate the most appropriate treatment and monitoring plans, based on patient-specific information and current guidelines for patients with diabetes.
  • Recommend appropriate modifications of patient-specific treatment plans based on follow-up assessment in patients with diabetes.

Planners, Presenters, and Reviewers

Full Faculty Bios

Professor, Department of Clinical and Administrative Sciences
Sullivan University College of Pharmacy
Cardiology Clinical Pharmacy Specialist
Jewish Hospital Rudd Heart and Lung Center
Louisville, Kentucky 
Associate Professor of Pharmacy Practice
Massachusetts College of Pharmacy and Health Science
Clinical Pharmacist
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Assistant Professor of Pharmacy Practice, Geriatrics & Pediatrics Division
Texas Tech University Health Sciences Center School of Pharmacy
Dallas, Texas
Professor and Director, Pharmacy Professional Development
University of Mississippi School of Pharmacy
Jackson, Mississippi
Clinical Pharmacist Practitioner, Oncology Supportive Care Consult Service
University of North Carolina Healthcare
Hillsborough, North Carolina
Director, Accreditation and Medication Safety
Cardinal Health Innovative Delivery Systems
Wilkes-Barre, Pennsylvania
Associate Professor
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, Colorado
Clinical Pharmacy Specialist
Denver Health Medical Center
Denver, Colorado
Associate Professor Midwestern University
Downers Grove, Illinois
Infectious Diseases Pharmacist
Northwestern Memorial Hospital
Chicago, Illinois
Professor and Infectious Diseases Clinical Specialist
West Virginia University (WVU) and WVU Hospitals and Clinics
Canonsburg, Pennsylvania
Infectious Diseases Clinical Pharmacy Specialist
Adult & Pediatric Infectious Diseases
Ochsner Medical Center
New Orleans, Louisiana
Associate Professor and Chair for the Department of Pharmacy Practice and Science
University of Maryland
Baltimore, Maryland

*Content matter experts

Susan R. Dombrowski, M.S., R.Ph.
Tony Martin, Pharm.D., M.B.A.
Anna M. Jackson, Pharm.D., BCPS
Kristi Hofer, Pharm.D.

Ahmed Abdeldayem, B.Sc.Pharm, BCPS
Ali Amin Daher Taha, Pharm.D., BCPS
Casey Anderson, Pharm.D., BCPS, BCOP
Alex Antell, Pharm.D. BCPS
Christina Berg, Pharm.D., BCPS, BCCCP
Kristen Bossert, Pharm.D., BCPS
Bazhena Brin, Pharm.D.,BCPS
Carrie Bruno, Pharm.D., BCPS
Candace Bryant, Pharm.D., BCPS
Christine Bui, Pharm.D., BCPS
Caitlin Cahayla, Pharm. D., BCPS
Amanda Chao, Pharm.D., BCPS
Brooklyn Cobb, Pharm.D., BCPS
Nathan Cope, Pharm.D., BCPS
Briana Coyne, Pharm.D., BCPS
Cassie Crew, Pharm.D., BCPS
Danhe Cui, Pharm.D., BCPS
Caitlyn Cummings, Pharm.D., BCPS
Ben Dagraedt, Pharm.D., M.B.A., BCPS
Annette Davis, R.Ph.,BCACP
Mary Dimaano, Pharm.D., BCPS
Bennett Doughty, Pharm.D., BCPS, BCPP
Aulbrey Drisaldi, Pharm.D., BCPS
Amy Ehlers, B.S., Pharm.D., BCPS
Christopher Ellison, Pharm.D., BCPS
Alireza FakhriRavari, Pharm.D., BCPS, BCIDP, AAHIVP
Michelle Fraley, Pharm.D., BCPS
Beth Fritsch, Pharm.D., M.B.A., BCPS
Kisha Gant, Pharm.D., BCACP, BCGP, BCPS
Bryan Gendron, Pharm.D., BCPS
Christina Gerber, Pharm.D., BCPS
Michael German, Pharm.D., BCPS
Amber Giles, Pharm.D., M.P.H., BCPS, AAHIVP
Christine Hancock, Pharm.D., BCPS
Nicole Humbert, Pharm.D., BCPS
Ada Jalice BSHS, Pharm.D., BCPS
Aamna Khan, Pharm.D., BCPS
Shilpa Klocke, Pharm.D., BCPS
Christine Lacki, Pharm.D., BCPS
Jeffrey Larsen, Pharm.D., BCPS
Brian LeBaron, Pharm.D., BCPS
Daisy Leong, Pharm.D., BCPS
Carolyn Lucchese, Pharm.D. , BCPS
Melanie Madorsky, Pharm.D., BCPS, BCCP
Adrienne Matson, Pharm.D., BCPS
Ana Miladinovic, Pharm.D. BCPS
Amy Montes, Pharm.D., BCPS., CPh.
Chidiya Ohiagu, Pharm.D., BCPS
Brittany Oliver, Pharm.D., BCPS
Cali Orsulak, BSCP
Cristina Patille, Pharm.D., BCPS
Cameron Patterson, Pharm.D., BCPS
Aaron Pavlik, Pharm.D., BCPS
Alexander Pease, Pharm.D., BCPS
Ashley Philibert, Pharm.D., BCPS
Alexas Polk, Pharm.D., BCPS
Ashley Powell, Pharm.D.
Joseph Remesz-Guerrette, Pharm.D., BCPS, BCNP
Ryan Rickles, Pharm.D., BCPS
Caley Roberts, Pharm.D., BCPS
Nancy Shulman, Pharm.D. BCPS
Brian Skinner, Pharm.D., BCPS
Adam Smith, Pharm.D., BCPS, BCCCP
Violetta Sobiech, Pharm.D., BCPS
Amber Soukkala Pharm.D, MPH, BCPS
Allison Steen, Pharm.D., BCPS
Marisa Strychalski, Pharm.D., BCPS, BCACP
Joe Tabler, Pharm.D., BCPS
Ashley Thomas, Pharm.D., BCPS, BCACP
Linsey Thompson, Pharm.D., BCPS
Alexander Tinios, Pharm.D. BCPS
Constance Topolewski Pharm.D, BCPS
Joan Viets, Pharm.D., BCPS
Betty Vu, Pharm.D., BCPS, BCIDP, AAHIVP
Brianne Wagner, Pharm.D., BCPS
Amanda Wannamaker, Pharm.D., BCPS
Corrie Weiland, Pharm.D., BCPS
Alexander Wilkocki, Pharm.D., M.B.A., BCPS
Daniel Wolverton Pharm.D., BCPS, BCACP, BC-ADM 

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Christopher Betz: Advisory Board, Portola Pharmaceuticals; Speaker Bureau, Janssen Pharmaceuticals, Inc.

All other planners, presenters, and reviewers of this session report no financial relationships relevant to this activity.

Methods and CE Requirements

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

System Technical Requirements

Learning activities are delivered via your Web browser and Acrobat PDF. For all activities you should have a basic comfort level using a computer and navigating web sites.

View the minimum technical and system requirements for learning activities.

Development

These activities were developed by ASHP.